Sagent Pharmaceuticals (Sagent) enlisted FTI to execute a hybrid perception study to gather investor intelligence pertaining to the company’s long-term strategic plan and its recent acquisition of a facility in China through both in-depth interviews and an online survey.
In-Depth Research: FTI spoke with 40 members of the investment community, including both current and past institutional investors, as well as key covering analysts of the equity research universe. Through both individual conversations and survey results, FTI assessed reaction and viewpoints on a variety of topics specific to Sagent, including the company’s long-term strategic growth objectives, valuation, guidance policies, the management team, and communications strategy.
Enhanced Investor Relations and Communications: As a result of the hybrid perception audit, Sagent’s executive team advanced the following recommendations to help improve specific investor relations and communications initiatives going forward:
© 2017 FTI Consulting, Inc. All Rights Reserved.